Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer

Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies. The DECISION trial was a multicenter, randomized, double-blind, placebo-controlled, Phase 3 trial which investigated sorafenib for treatment of progressive, advanced, or metastatic radioactive iodine...

Descripción completa

Detalles Bibliográficos
Autores principales: Worden, Francis, Fassnacht, Martin, Shi, Yuankai, Hadjieva, Tatiana, Bonichon, Françoise, Gao, Ming, Fugazzola, Laura, Ando, Yuichi, Hasegawa, Yasuhisa, Park, Do Joon, Shong, Young Kee, Smit, Johannes W A, Chung, John, Kappeler, Christian, Meinhardt, Gerold, Schlumberger, Martin, Brose, Marcia S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570090/
https://www.ncbi.nlm.nih.gov/pubmed/26370187
http://dx.doi.org/10.1530/ERC-15-0252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4570090/
https://www.ncbi.nlm.nih.gov/pubmed/26370187
http://dx.doi.org/10.1530/ERC-15-0252

Ejemplares similares